🔎 Trials Near Me

Почетна › Рак на дојка › Пенсилванија

Клинички испитувања за Рак на дојка во Пенсилванија

93 студии за Рак на дојка бараат учесници на локации во Пенсилванија.

Градови во Пенсилванија

Официјален текст на студијата (англиски)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
  • University of Pittsburgh Medical Center, Pittsburgh
  • WellSpan York Cancer Center, York
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750

Distance-Based Exercise to Preserve Function and Prevent Disability

  • UPMC Hillman Cancer Center at Butler Health System, Butler
  • IRMC Cancer Center, Indiana
  • UPMC Hillman Cancer Center - New Castle, New Castle
  • и уште 2
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07059884

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

  • Consultants In Med Onco And Hema, Drexel Hill
  • Univ of Pittsburg Med Ctr Pinnacle, Harrisburg
  • Allegheny Health Network, Pittsburgh
Се регрутираФаза 3
Возраст од 18 до 100 · Сите полови · Ажурирано 2.10.2026 · NCT05827081

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

  • Lehigh Valley Health Network (Data Collection Only), Allentown
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT05534438

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Geisinger Medical Center, Danville
  • и уште 7
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • Alliance Cancer Specialists, Horsham
  • University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia
  • University of Pittsburgh (UPMC), Pittsburgh
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06369285

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Penn State Milton S. Hershey Medical Center, Hershey
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT06324357

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

  • Allegheny General Hospital, Pittsburgh
Се регрутираНабљудувачка студија
Возраст од 20 до 89 · Жени · Ажурирано 30.9.2026 · NCT07023887

A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer

  • AHN Allegheny General Hospital, Pittsburgh
  • Allegheny General Hospital, Pittsburgh
Се регрутира
Возраст од 20 до 89 · Жени · Ажурирано 30.9.2026 · NCT07698314

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Pittsburgh
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT05877599

EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer

  • AHN Allegheny General Hospital, Pittsburgh
  • AHN Allegheny General Hospital, Pittsburgh
Се регрутира
Возраст од 20 до 89 · Жени · Ажурирано 28.9.2026 · NCT07704476

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Philadelphia
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT05867251

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  • University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058), Pittsburgh
  • Cancer Care Associates Of York ( Site 0063), York
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07060807

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Се регрутира
Возраст 30 и постари · Жени · Ажурирано 25.9.2026 · NCT02945579

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  • Thomas Jefferson University - Clinical Research Institute ( Site 0056), Philadelphia
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06312176

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

  • Penn Medicine - Lancaster General Hospital, Lancaster
  • Capital Health Hematology Oncology Specialists, Newton
  • Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia
  • и уште 2
Се регрутираФаза 3
Возраст 60 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06377852

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  • Clinical Trial Site, Horsham
  • Clinical Trial Site, Sayre
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Allegheny (AHN), Pittsburgh
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • St. Luke's University Health Network, Bethlehem
  • Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
  • University of Pennsylvania Hospital, Philadelphia
  • и уште 3
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07174336

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • University of Pittsburgh Medical Center, Pittsburgh
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • University of Pennsylvania, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07213791

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT07340541

Identifying Patterns in the Breath of Individuals With Breast Cancer

  • Weinstein Imaging Associates, Pittsburgh
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 40 до 74 · Жени · Ажурирано 18.9.2026 · NCT06512350

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • Lehigh Valley Health Network - Cedar Crest, Allen
  • Consultants In Medical Oncology and Hematology, P.C., Broomall
  • Penn State Milton S. Hershey Medical Center, Hershey
  • и уште 5
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT06492616

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, Pittsburgh
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT05123482

Active Surveillance in Older Women With ER+ Breast Cancer

  • University of Pittsburgh Medical Center, Pittsburgh
Се регрутираНабљудувачка студија
Возраст 70 и постари · Жени · Ажурирано 11.9.2026 · NCT07262138

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

  • St. Luke's University Health Network, Bethlehem
  • Guthrie Medical Group, Sayre
Се регрутираФаза 1
Возраст од 18 до 55 · Жени · Ажурирано 9.9.2026 · NCT07310420

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

  • Penn State Health Milton S. Hershey Medical Center, Hershey
  • University of Pennsylvania - Abramson Cancer Center, Philadelphia
  • UPMC - Hillman Cancer Center, Pittsburgh
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT07100106

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

  • University of Pennsylvania, Philadelphia
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT05315700

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

  • Penn State Cancer Institute, Hershey
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT04886531

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • UPMC Hillman Cancer Center - Magee-Women?s Hospital, Pittsburgh
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06790693

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 2.9.2026 · NCT07216105

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

  • Abramson Cancer Center, Philadelphia
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 2.9.2026 · NCT05964504

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Bryn Mawr Hospital, Bryn Mawr
  • и уште 56
Се регрутираФаза 3
Возраст од 18 до 60 · Жени · Ажурирано 2.9.2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • UPMC Hillman Cancer Center, Pittsburgh
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT07029399

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
  • UPMC, Pittsburgh
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 21.8.2026 · NCT06774963

Biennial CEM in Women With a Personal History of Breast Cancer

  • UPMC Magee-Womens Imaging - Bethel Park, Bethel Park
  • UPMC Magee at the Lemieux Sports Complex, Cranberry Township
  • Magee Womancare Monroeville, Monroeville
  • и уште 3
Се регрутираДобредојдени се здрави волонтери
Возраст од 30 до 79 · Жени · Ажурирано 19.8.2026 · NCT06105749

ATEMPT 2.0: Adjuvant T-DM1 vs TH

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia
  • University of Pittsburgh Medical Center Cancer UPMC- Magee Women's Hospital, Pittsburgh
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT04893109

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT02732171

EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer

  • AHN Allegheny General Hospital, Pittsburgh
Се регрутира
Возраст од 20 до 89 · Жени · Ажурирано 17.8.2026 · NCT07739563

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.